NcXHF

CHEMOTHERAPY FOR PATIENTS WITH BMOC
30. Safra T, Rogowski O, Muggia FM. The effect of germ-line BRCA mutations
on response to chemotherapy and outcome of recurrent ovarian
cancer. Int J Gynecol Cancer. 2014;24:488-495.
31. Rose PG. Pegylated liposomal doxorubicin: optimizing the dosing
schedule in ovarian cancer. Oncologist. 2005;10:205-214.
32. Thorn CF, Oshiro C, Marsh S, et al. Doxorubicin pathways: pharmacodynamics
and adverse effects. Pharmacogenet Genomics. 2011;21:440-
446.
33. Mantia-Smaldone G, Ronner L, Blair A, et al. The immunomodulatory
effects of pegylated liposomal doxorubicin are amplifıed in BRCA1-
defıcient ovarian tumors and can be exploited to improve treatment response
in a mouse model. Gynecol Oncol. 2014;133:584-590.
34. del Campo JM, Sessa C, Krasner CN, et al. Trabectedin as single agent in
relapsed advanced ovarian cancer: results from a retrospective pooled
analysis of three phase II trials. Med Oncol. 2013;30:435.
35. Krasner CN, McMeekin DS, Chan S, et al. A Phase II study of trabectedin
single agent in patients with recurrent ovarian cancer previously
treated with platinum-based regimens. Br J Cancer. 2007;97:1618-1624.
36. Monk BJ, Ghatag P, Parekh T, et al. Effect of BRCA1 and XPG mutations
on treatment response to trabectedin and pegylated liposomal doxorubicin
in subjects with advanced ovarian cancer: exploratory analysis of
phase III OVA-301 study. Paper presented at: 45th Annual Meeting of
Society of Gynecologic Oncology; March 2014; Tampa, FL.
37. Yun J, Zhong Q, Kwak JY, et al. Hypersensitivity of BRCA1-defıcient
MEF to the DNA interstrand crosslinking agent mitomycin C is associated
with defect in homologous recombination repair and aberrant
S-phase arrest. Oncogene. 2005;24:4009-4016.
38. Evers B, Schut E, van der Burg E, et al. A high-throughput pharmaceutical
screen identifıes compounds with specifıc toxicity against BRCA2-
defıcient tumors. Clin Cancer Res. 2010;16:99-108.
39. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and
cisplatin compared with paclitaxel and cisplatin in patients with stage III
and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6.
40. Baird RD, Tan DS, Kaye SB. Weekly paclitaxel in the treatment of recurrent
ovarian cancer. Nat Rev Clin Oncol. 2010;7:575-582.
41. Tagliaferri P, Ventura M, Baudi F, et al. BRCA1/2 genetic backgroundbased
therapeutic tailoring of human ovarian cancer: hope or reality?
J Ovarian Res. 2009;2:14.
42. Quinn JE, James CR, Stewart GE, et al. BRCA1 mRNA expression levels
predict for overall survival in ovarian cancer after chemotherapy. Clin
Cancer Res. 2007;13:7413-7420.
43. Quinn JE, Carser JE, James CR, et al. BRCA1 and implications for response
to chemotherapy in ovarian cancer. Gynecol Oncol. 2009;113:
134-142.
44. Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates
chemosensitivity of BRCA1-defective HCC1937 human breast cancer
cells. Br J Cancer. 2003;88:1285-1291.
45. Chabalier C, Lamare C, Racca C, et al. BRCA1 downregulation leads to
premature inactivation of spindle checkpoint and confers paclitaxel resistance.
Cell Cycle. 2006;5:1001-1007.
46. Zhou C, Smith JL, Liu J. Role of BRCA1 in cellular resistance to paclitaxel
and ionizing radiation in an ovarian cancer cell line carrying a defective
BRCA1. Oncogene. 2003;22:2396-2404.
47. Sylvain V, Lafarge S, Bignon YJ. Dominant-negative activity of a BRCA1
truncation mutant: effects on proliferation, tumorigenicity in vivo, and
chemosensitivity in a mouse ovarian cancer cell line. Int J Oncol. 2002;
20:845-853.
48. Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel
versus carboplatin plus pegylated liposomal doxorubicin as fırst-line
treatment for patients with ovarian cancer: the MITO-2 randomized
phase III trial. J Clin Oncol. 2011;29:3628-3635.
49. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal
doxorubicin and carboplatin compared with paclitaxel and
carboplatin for patients with platinum-sensitive ovarian cancer in late
relapse. J Clin Oncol. 2010;28:3323-3329.
50. Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dosedense
paclitaxel and carboplatin versus conventional paclitaxel and carboplatin
for treatment of advanced epithelial ovarian, fallopian tube, or
primary peritoneal cancer (JGOG 3016): a randomised, controlled,
open-label trial. Lancet Oncol. 2013;14:1020-1026.
51. Armstrong DK, Fujiwara K, Jelovac D. Intraperitoneal treatment in
ovarian cancer: the gynecologic oncology group perspective in 2012.
Am Soc Clin Oncol Educ Book. 2012;32:345-348.
52. Lesnock JL, Darcy KM, Tian C, et al. BRCA1 expression and improved
survival in ovarian cancer patients treated with intraperitoneal cisplatin
and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer. 2013;
108:1231-1237.
53. Ledermann JA, Gabra H, Jayson GC, et al. Inhibition of carboplatininduced
DNA interstrand cross-link repair by gemcitabine in patients
receiving these drugs for platinum-resistant ovarian cancer. Clin Cancer
Res. 2010;16:4899-4905.
54. Sharma R, Graham J, Mitchell H, et al. Extended weekly dose-dense paclitaxel/carboplatin
is feasible and active in heavily pre-treated platinumresistant
recurrent ovarian cancer. Br J Cancer. 2009;100:707-712.
55. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined
with chemotherapy for platinum-resistant recurrent ovarian cancer:
the AURELIA open-label randomized phase III trial. J Clin Oncol.
2014;32:1302-1308.
56. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy
in patients with advanced cancer and germline BRCA 1/2 mutation.
J Clin Onc. 2015;33:244-250.
57. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy
in patients with platinum-sensitive relapsed serous ovarian cancer: a
preplanned retrospective analysis of outcomes by BRCA status in a randomised
phase 2 trial. Lancet Oncol. 2014;15:852-861.
58. Perren TJ, Swart AM, Pfısterer J, et al. A phase 3 trial of bevacizumab in
ovarian cancer. N Engl J Med. 2011;365:2484-2496.
59. Ang JE, Gourley C, Powell CB, et al. Effıcacy of chemotherapy in
BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor
resistance: a multi-institutional study. Clin Cancer Res. 2013;19:
5485-5493.
60. Sandhu SK, Omlin A, Hylands L, et al. Poly (ADP-ribose) polymerase
(PARP) inhibitors for the treatment of advanced germline BRCA2 mutant
prostate cancer. Ann Oncol. 2013;24:1416-1418.
61. Bhalla A, Saif MW. PARP-inhibitors in BRCA-associated pancreatic
cancer. JOP. 2014;15:340-343.
62. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase
inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and
advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376:235-
244.
63. Turner N, Tutt A, Ashworth A. Hallmarks of “BRCAness” in sporadic
cancers. Nat Rev Cancer. 2004;4:814-819.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK 121